Bortezomib in the Treatment of Multiple Myeloma

1. Front Matter

   Pages i-viii

   PDF

2. Bortezomib’s Scientific Origins and Its Tortuous Path to the Clinic

   • Alfred L. Goldberg

   Pages 1-27

3. Preclinical Activities of Bortezomib in MM, the Bone Marrow Microenvironment and Pharmacogenomics

   • Teru Hideshima, Paul G. Richardson, Kenneth C. Anderson

   Pages 29-42

4. Bortezomib and Osteoclasts and Osteoblasts

   • Michal T. Krauze, G. David Roodman

   Pages 43-52

5. Bortezomib in the Upfront Treatment of Multiple Myeloma

   • Jesús F. San Miguel, María -Victoria Mateos

   Pages 53-68

6. The Use of Bortezomib in Autologous Transplantation for Multiple Myeloma

   • Amelia A. Langston, Sagar Lonial

   Pages 69-77

7. Bortezomib in Relapsed and Relapsed/Refractory Multiple Myeloma

   • Jatin J. Shah, Robert Z. Orlowski

   Pages 79-94

8. Bortezomib-Induced Peripheral Neuropathy in Multiple Myeloma: Principles of Identification and Management

   • Jacob P. Laubach, Paul G. Richardson

   Pages 95-105

9. Bortezomib in Mantle Cell Lymphoma

   • Andre Goy

   Pages 107-121

10. Bortezomib in Waldenstrom’s Macroglobulinemia

    • Irene M. Ghobrial, Aldo M. Roccaro, Xavier Leleu

    Pages 123-133

11. Bortezomib in Systemic Light-Chain Amyloidosis

    • Morie A. Gertz, Raymond Comenzo

    Pages 135-148

12. Second-Generation Proteasome Inhibitors

    • Dixie-Lee Esseltine, Larry Dick, Erik Kupperman, Mark Williamson, Kenneth C. Anderson

    Pages 149-176

13. Back Matter

    Pages 177-179

    PDF

Multiple Myeloma (MM) is the second most common type of blood cancer, resulting from an overproduction of cancerous infection-fighting white blood cells, known as plasma cells. Plasma cells are a crucial part of the immune system responsible for the production of antibodies. Bortezomib is a promising anticancer drug targeting the proteasome. This proteasome inhibitor induces cell stress and apoptosis in the cancer cells. While multiple mechanisms are likely to be involved, proteasome inhibition may prevent the degradation of pro-apoptotic factors, permitting activation of programmed cell death in neoplastic cells dependent upon the suppression of proapoptotic pathways. This monograph on bortezomib is a valuable source of information for researchers and clinicians from the fields of oncology and pharmacology, working either in academia or the pharmaceutical industry.

• Bortezomib
• Cancer therapy
• Multiple Myeloma
• Oncology
• Pharmacology
• Proteasome inhibitors
• Velcade
• Apoptosis

• Dana-Farber Cancer Institute, Dept. Medical Oncology, Harvard Medical School, Boston, USA

  Irene M. Ghobrial, Paul G. Richardson, Kenneth C. Anderson

Policies and ethics